Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Adipocyte FABP (FABP4) Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Adipocyte-type fatty acid-binding protein, A-FABP, Fatty acid-binding protein 4, Adipocyte lipid-binding protein, ALBP, FABP4
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

RD191036200R 96 wells (1 kit)
PubMed Product Details
Technical Data


Sandwich ELISA, Biotin-labelled antibody


Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate

Sample Requirements

20 µl/well


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.5–25 ng/ml

Limit of Detection

0.05 ng/ml

Intra-assay (Within-Run)

n = 8; CV = 2.5%

Inter-assay (Run-to-Run)

n = 3; CV = 3.9%

Spiking Recovery


Dilutation Linearity



  • bovine Non-detectable
  • cat None-specific binding
  • goat Non-detectable
  • hamster Non-detectable
  • horse Non-detectable
  • dog Yes (recommended dilution 1:3)
  • pig Non-detectable
  • rabbit Non-detectable
  • rat Non-detectable
  • sheep Non-detectable
  • chicken Not tested
  • human Yes
  • mouse Yes
  • monkey Yes (recommended dilution 1:3)


  • It is intended for research use only
  • The total assay time is less than 4 hours
  • The kit measures total AFABP in serum and plasma (EDTA, citrate, heparin)
  • Assay format is 96 wells
  • Quality Controls are human serum based
  • Standard is recombinant protein based
  • Components of the kit are provided ready to use, concentrated or lyophilized
  • EU Patent Number: EP1904082

Research topic

Diabetology - Other Relevant Products, Energy metabolism and body weight regulation


Adipocyte fatty acid binding protein AFABP is a 15 kDa member of the intracellular fatty acid binding protein (FABP) family, which is known for the ability to bind fatty acids and related compounds (bile acids or retinoids) in an internal cavity. AFABP is expressed in a differentiation-dependent fashion in adipocytes and is a critical gene in the regulation of the biological function of these cells. In mice, targeted mutations in FABP4 (mouse gene is also called aP2 and its relevant protein P2 adipocyte protein or 3T3-L1 lipid binding protein) provide significant protection from hyperinsulinemia and insulin resistance in the context of both dietary and genetic obesity. Adipocytes obtained from AFABP-deficient mice also have reduced efficiency of lipolysis in vitro and in vivo, and these mice exhibited moderately improved systemic dyslipidemia. Recent studies also demonstrated AFABP expression in human macrophages upon differentiation and activation. In these cells, AFABP modulates inflammatory responses and cholesterol ester accumulation, and total or macrophage-specific AFABP deficiency confers dramatic protection against atherosclerosis in the apoE-/- mice. These results indicate a central role for AFABP in the development of major components of the metabolic syndrome through its distinct actions in adipocytes and macrophages.

Besides being active within the cell, AFABP appears to be a secreted protein (for normal levels and correlations with certain metabolic parameters see chapter 15). The extracellular role of secreted AFABP remains to be determined.

References to Product


  • Aeberli I, Beljean N, Lehmann R, I'Allemand D, Spinas GA, Zimmermann MB. The increase of fatty acid-binding protein aP2 in overweight and obese children: interactions with dietary fat and impact on measures of subclinical inflammation. Int J Obes (Lond). 2008 Oct;32 (10):1513-20
  • Andres Cerezo L, Kuklova M, Hulejova H, Vernerova Z, Pesakova V, Pecha O, Veigl D, Haluzik M, Pavelka K, Vencovsky J, Senolt L. The level of fatty acid-binding protein 4, a novel adipokine, is increased in rheumatoid arthritis and correlates with serum cholesterol levels. Cytokine. 2013 Oct;64 (1):441-7
  • Aragones G, Ferre R, Lazaro I, Cabre A, Plana N, Merino J, Heras M, Girona J, Masana L. Fatty acid-binding protein 4 is associated with endothelial dysfunction in patients with type 2 diabetes. Atherosclerosis. 2010 Nov;213 (1):329-31
  • Aragones G, Saavedra P, Heras M, Cabre A, Girona J, Masana L. Fatty acid-binding protein 4 impairs the insulin-dependent nitric oxide pathway in vascular endothelial cells. Cardiovasc Diabetol. 2012;11:72
  • Baessler A, Lamounier-Zepter V, Fenk S, Strack C, Lahmann C, Loew T, Schmitz G, Bluher M, Bornstein SR, Fischer M. Adipocyte fatty acid-binding protein levels are associated with left ventricular diastolic dysfunction in morbidly obese subjects. Nutr Diabetes. 2014;4:e106
  • Bagheri R, Qasim AN, Mehta NN, Terembula K, Kapoor S, Braunstein S, Schutta M, Iqbal N, Lehrke M, Reilly MP. Relation of plasma fatty acid binding proteins 4 and 5 with the metabolic syndrome, inflammation and coronary calcium in patients with type-2 diabetes mellitus. Am J Cardiol. 2010 Oct 15;106 (8):1118-23
  • Bao Y, Lu Z, Zhou M, Li H, Wang Y, Gao M, Wei M, Jia W. Serum levels of adipocyte fatty acid-binding protein are associated with the severity of coronary artery disease in Chinese women. PLoS One. 2011;6 (4):e19115
  • Ben Yahia R, Lichnovska R, Gwozdiewiczova S, Kuzmina G, Chlup R, Luza J, Karpisek M, Brychta T, Petrek J. Fatty Acid Binding Proteins (FABPS) in relation to significant metabolic syndrome markers in diabetic patients and non-diabetic persons - pilot study. Int J Obesity . 29: S1-S19
  • Ben Yahia R, Lichnovska R, Janusova L, Kuzmina G, Karpisek M, Kollar P, Petrek J. Healthy persons versus patients with diabetes mellitus type 2--choosen parameters in serum and subcutaneous abdominal adipose tissue. Vnitr Lek. Jan;53(1):9, 11-7 (2007)
  • Bol VV, Delattre AI, Reusens B, Raes M, Remacle C. Forced catch-up growth after fetal protein restriction alters the adipose tissue gene expression program leading to obesity in adult mice. Am J Physiol Regul Integr Comp. 2009 Aug;297 (2):R291-9
  • Breitling LP, Salzmann K, Rothenbacher D, Burwinkel B, Brenner H. Smoking, F2RL3 methylation, and prognosis in stable coronary heart disease. Eur Heart J. 2012 Apr 17;
  • Bronsky J, Karpisek M, Bronska E, Pechova M, Jancikova B, Kotolova H, Stejskal D, Prusa R, Nevoral J. Adiponectin, adipocyte fatty acid binding protein, and epidermal fatty acid binding protein: proteins newly identified in human breast milk. Clin Chem . Sep;52(9):1763-70 (2006)
  • Bronsky J, Mitrova K, Karpisek M, Mazoch J, Durilova M, Fisarkova B, Stechova K, Prusa R, Nevoral J. Adiponectin, AFABP, and leptin in human breast milk during 12 months of lactation. J Pediatr Gastroenterol Nutr. 2011 Apr;52 (4):474-7
  • Burak MF, Inouye KE, White A, Lee A, Tuncman G, Calay ES, Sekiya M, Tirosh A, Eguchi K, Birrane G, Lightwood D, Howells L, Odede G, Hailu H, West S, Garlish R, Neale H, Doyle C, Moore A, Hotamisligil GS. Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. Sci Transl Med. 2015 Dec 23;7 (319):319ra205
  • Cabre A, Babio N, Lazaro I, Bullo M, Garcia-Arellano A, Masana L, Salas-Salvado J. FABP4 predicts atherogenic dyslipidemia development. The PREDIMED study. Atherosclerosis. 2012 May;222 (1):229-34
  • Cabre A, Lazaro I, Cofan M, Jarauta E, Plana N, Garcia-Otin AL, Ascaso JF, Ferre R, Civeira F, Ros E, Masana L. FABP4 plasma levels are increased in familial combined hyperlipidemia. J Lipid Res. 2010 May;51 (5):1173-8
  • Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, Guardiola M, Heras M, Masana L. The APOA5-1131 T>C variant enhances the association between RBP4 and hypertriglyceridemia in diabetes. Nutr Metab Cardiovasc Dis. 2010 May;20 (4):243-8
  • Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, Heras M, Masana L. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis . Nov;195(1):e150-e158 (2007)
  • Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, Heras M, Masana L. Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. J Lipid Res. 2008 Aug;49 (8):1746-51
  • Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, Heras M, Masana L. Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria. Clin Chem . Jan;54(1):181-7 (2008)
  • Carruthers N, Booy A, Ballard J, Siroen DM, Han VK, Lajoie GA. Early onset preeclampsia is characterized by altered placental lipid metabolism and a premature increase in circulating FABP4. Nature Precedings. 2010;hdl:10101/npre.2010.4885.1
  • Castro A, Lazaro I, Selva DM, Cespedes E, Girona J, NuriaPlana, Guardiola M, Cabre A, Simo R, Masana L. APOH is increased in the plasma and liver of type 2 diabetic patients with metabolic syndrome. Atherosclerosis. 2010 Mar;209 (1):201-5
  • Chen MC, Hsu BG, Lee CJ, Yang CF, Wang JH. High serum adipocyte fatty acid binding protein level as a potential biomarker of aortic arterial stiffness in hypertensive patients with metabolic syndrome. Clin Chim Acta. 2017 Oct;473:166-172. doi: 10.1016/j.cca.2017.08.030. Epub 2017 Aug 30. PubMed PMID: 28860092.
  • Choi KM, Kim TN, Yoo HJ, Lee KW, Cho GJ, Hwang TG, Baik SH, Choi DS, Kim SM. Effect of exercise training on A-FABP, lipocalin-2 and RBP4 levels in obese women. Clin Endocrinol (Oxf). 2009 Apr;70 (4):569-74
  • Ciardi C, Tatarczyk T, Tschoner A, Kranebitter M, Niederwanger A, Ebenbichler CF, Patsch JR, Pedrini MT. Effect of postprandial lipemia on plasma concentrations of A-FABP, RBP-4 and visfatin. Nutr Metab Cardiovasc Dis. 2009 Aug 20;
  • Coll B, Cabre A, Alonso-Villaverde C, Lazaro I, Aragones G, Parra S, Girona J, Masana L. The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. Atherosclerosis . Nov 3 (2007)
  • Corripio R, Gonzalez-Clemente JM, Perez-Sanchez J, Naf S, Gallart L, Nosas R, Vendrell J, Caixas A. Weight loss in prepubertal obese children is associated with a decrease in adipocyte fatty-acid-binding protein without changes in lipocalin-2: a 2-year longitudinal study. Eur J Endocrinol. 2010 Dec;163 (6):887-93
  • Creagan ET, Chang M, Long HJ, Rubin J. Phase II clinical trial of the combination VP-16, bleomycin, and cis-diamminedichloroplatinum in patients with advanced upper aerodigestive squamous cell carcinoma. Head Neck Surg. 1987 Mar-Apr;9 (4):223-6
  • Danziger J, Biggs ML, Niemi M, Ix JH, Kizer JR, Djousse L, de Boer IH, Siscovick DS, Kestenbaum B, Mukamal KJ. Circulating 25-hydroxyvitamin D is associated with insulin resistance cross-sectionally but not longitudinally in older adults: The Cardiovascular Health Study. Metabolism. 2013 Aug 26;
  • Djousse L, Maziarz M, Biggs ML, Ix JH, Zieman SJ, Kizer JR, Lemaitre RN, Mozaffarian D, Tracy RP, Mukamal KJ, Siscovick DS, Sotoodehnia N. Plasma Fatty Acid binding protein 4 and risk of sudden cardiac death in older adults. Cardiol Res Pract. 2013;2013:181054
  • Durovcova V, Marek J, Hana V, Matoulek M, Zikan V, Haluzikova D, Kavalkova P, Lacinova Z, Krsek M, Haluzik M. Plasma concentrations of adipocyte fatty acid binding protein in patients with Cushing's syndrome. Physiol Res. 2010;59 (6):963-71
  • Ebert T, Hopf LM, Wurst U, Bachmann A, Kralisch S, Lossner U, Platz M, Kratzsch J, Stolzenburg JU, Dietel A, Grisk O, Beige J, Anders M, Bast I, Kloting N, Bluher M, Stumvoll M, Fasshauer M. Circulating adipocyte fatty acid binding protein is increased in chronic and acute renal dysfunction. Nutr Metab Cardiovasc Dis. 2014 Sep;24 (9):1027-34
  • Engl J, Ciardi C, Tatarczyk T, Kaser S, Laimer M, Laimer E, Weiss H, Aigner F, Molnar C, Tilg H, Patsch JR, Ebenbichler CF. A-FABP--a biomarker associated with the metabolic syndrome and/or an indicator of weight change?. Obesity (Silver Spring). 2008 Aug;16 (8):1838-42
  • Engl J, Tschoner A, Willis M, Schuster I, Kaser S, Laimer M, Biebl W, Patsch JR, Mangweth B, Ebenbichler CF. Adipocyte fatty acid binding protein during refeeding of female patients with anorexia nervosa. Eur J Nutr. 2009 Oct;48 (7):403-8
  • Fain JN, Tagele BM, Cheema P, Madan AK, Tichansky DS. Release of 12 Adipokines by Adipose Tissue, Nonfat Cells, and Fat Cells From Obese Women. Obesity (Silver Spring). 2009 Oct 15;
  • Fasshauer M, Seeger J, Waldeyer T, Schrey S, Ebert T, Kratzsch J, Lossner U, Bluher M, Stumvoll M, Faber R, Stepan H. Serum levels of the adipokine adipocyte fatty acid-binding protein are increased in preeclampsia. Am J Hypertens. 2008 May;21 (5):582-6
  • Furuhashi M, Ishimura S, Ota H, Hayashi M, Nishitani T, Tanaka M, Yoshida H, Shimamoto K, Hotamisligil GS, Miura T. Serum Fatty Acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease. PLoS One. 2011;6 (11):e27356
  • Fuseya T, Furuhashi M, Yuda S, Muranaka A, Kawamukai M, Mita T, Ishimura S, Watanabe Y, Hoshina K, Tanaka M, Ohno K, Akasaka H, Ohnishi H, Yoshida H, Saitoh S, Shimamoto K, Miura T. Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population. Cardiovasc Diabetol. 2014;13 (1):126
  • Gul O, Calay E, Sezerman U, Basaga H, Gurbuz Y. Sandwich-type, antibody microarrays for the detection and quantification of cardiovascular risk markers. Chemical . Aug 125(2):581-588 (2007)
  • Haider DG, Schindler K, Bohdjalian A, Prager G, Luger A, Wolzt M, Ludvik B. Plasma adipocyte and epidermal fatty acid binding protein is reduced after weight loss in obesity. Diabetes Obes Metab . Mar 13 (2007)
  • Haluzik MM, Anderlova K, Dolezalova R, Adamikova A, Haluzikova D, Housova J, Svacina S, Haluzik M. Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment. Physiol Res. 2009;58 (1):93-9
  • Haluzikova D, Dostalova I, Kavalkova P, Roubicek T, Mraz M, Papezova H, Haluzik M. Serum concentrations of adipocyte fatty acid binding protein in patients with anorexia nervosa. Physiol Res. 2009;58 (4):577-81
  • Hancke K, Grubeck D, Hauser N, Kreienberg R, Weiss JM. Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res Treat. 2010 Jan;119 (2):367-7
  • Hao Y, Ma X, Luo Y, Hu X, Pan X, Xiao Y, Bao Y, Jia W. Associations of serum adipocyte fatty acid binding protein with body composition and fat distribution in nondiabetic Chinese women. J Clin Endocrinol Metab. 2015 May;100 (5):2055-62
  • Horakova D, Pastucha D, Stejskal D, Kollarova H, Azeem K, Janout V. Adipocyte fatty acid binding protein and C-reactive protein levels as indicators of insulin resistance development. Biomed Pap Med Fac Univ Palack. 2011 Dec;155 (4):355-9
  • Horakova D, Stejskal D, Pastucha D, Muchova L, Janout V. Potential markers of insulin resistance in healthy vs obese and overweight subjects. Biomed Pap Med Fac Univ Palack. 2010 Sep;154 (3):245-9
  • Hsu BG, Chen YC, Lee RP, Lee CC, Lee CJ, Wang JH. Fasting serum level of Fatty-Acid-binding protein 4 positively correlates with metabolic syndrome in patients with coronary artery disease. Circ J. 2010 Feb;74 (2):327-31
  • Huang CL, Wu YW, Hsieh AR, Hung YH, Chen WJ, Yang WS. Serum adipocyte fatty acid-binding protein levels in patients with critical illness are associated with insulin resistance and predict mortality. Crit Care. 2013 Feb 1;17 (1):R22
  • Huang CL, Wu YW, Wu CC, Lin L, Wu YC, Hsu PY, Jong YS, Yang WS. Association between serum adipocyte fatty-acid binding protein concentrations, left ventricular function and myocardial perfusion abnormalities in patients with coronary artery disease. Cardiovasc Diabetol. 2013;12:105
  • Hung CS, Wu YW, Huang JY, Hsu PY, Chen MF. Evaluation of circulating adipokines and abdominal obesity as predictors of significant myocardial ischemia using gated single-photon emission computed tomography. PLoS One. 2014;9 (5):e97710
  • Ishimura S, Furuhashi M, Watanabe Y, Hoshina K, Fuseya T, Mita T, Okazaki Y, Koyama M, Tanaka M, Akasaka H, Ohnishi H, Yoshida H, Saitoh S, Miura T. Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. PLoS One. 2013;8 (11):e81318
  • Iso T, Sunaga H, Matsui H, Kasama S, Oshima N, Haruyama H, Furukawa N, Nakajima K, Machida T, Murakami M, Yokoyama T, Kurabayashi M. Serum levels of fatty acid binding protein 4 and fat metabolic markers in relation to catecholamines following exercise. Clin Biochem. 2017 Nov;50(16-17):896-902. doi: 10.1016/j.clinbiochem.2017.05.021. Epub 2017 Jun 2. PubMed PMID: 28583436.
  • Iwamoto M, Miyoshi T, Doi M, Takeda K, Kajiya M, Nosaka K, Nakayama R, Hirohata S, Usui S, Kusachi S, Sakane K, Nakamura K, Ito H. Elevated serum adipocyte fatty acid-binding protein concentrations are independently associated with renal dysfunction in patients with stable angina pectoris. Cardiovasc Diabetol. 2012 Mar 21;11 (1):26
  • Jeon WS, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Lee WY. Association of serum adipocyte-specific Fatty Acid binding protein with Fatty liver index as a predictive indicator of nonalcoholic Fatty liver disease. Endocrinol Metab (Seoul). 2013 Dec;28 (4):283-7
  • Jin J, Peng DQ, Yuan SG, Zhao SP, Ning XH, Wang SH, Li SL. Serum adipocyte fatty acid binding proteins and adiponectin in patients with coronary artery disease: the significance of A-FABP/adiponectin ratio. Clin Chim Acta. 2010 Nov 11;411 (21-22):1761-5
  • Kaess BM, Enserro DM, McManus DD, Xanthakis V, Chen MH, Sullivan LM, Ingram C, O'Donnell CJ, Keaney JF, Vasan RS, Glazer NL. Cardiometabolic correlates and heritability of fetuin-a, retinol-binding protein 4, and Fatty-Acid binding protein 4 in the framingham heart study. J Clin Endocrinol Metab. 2012 Oct;97 (10):E1943-7
  • Karakas SE, Almario RU, Kim K. Serum fatty acid binding protein 4, free fatty acids, and metabolic risk markers. Metabolism. 2009 Jul;58 (7):1002-7
  • Karpisek M, Stejskal D, Kotolova H, Kollar P, Janoutova G, Ochmanova R, Cizek L, Horakova D, Yahia RB, Lichnovska R, Janout V. Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia. Eur J Clin Invest . Aug;37(8):637-42 (2007)
  • Kim TN, Won JC, Kim YJ, Lee EJ, Kim MK, Park MS, Lee SK, Kim JM, Ko KS, Rhee BD. Serum adipocyte fatty acid-binding protein levels are independently associated with sarcopenic obesity. Diabetes Res Clin Pract. 2013 Aug;101 (2):210-7
  • Kim YC, Cho YK, Lee WY, Kim HJ, Park JH, Park DI, Sohn CI, Jeon WK, Kim BI, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Kim SW, Ryu SH. Serum adipocyte-specific fatty acid-binding protein is associated with nonalcoholic fatty liver disease in apparently healthy subjects. J Nutr Biochem. 2011 Mar;22 (3):289-92
  • Koh JH, Shin YG, Nam SM, Lee MY, Chung CH, Shin JY. Serum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients. Diabetes Care. 2009 Jan;32 (1):147-52
  • Kotulak T, Drapalova J, Lips M, Lacinova Z, Kramar P, Riha H, Netuka I, Maly J, Blaha J, Lindner J, Svacina S, Mraz M, Haluzik M. Cardiac surgery increases serum concentrations of adipocyte fatty acid-binding protein and its mRNA expression in circulating monocytes but not in adipose tissue. Physiol Res. 2014;63 (1):83-94
  • Kralisch S, Ebert T, Lossner U, Jessnitzer B, Stumvoll M, Fasshauer M. Adipocyte fatty acid-binding protein is released from adipocytes by a non-conventional mechanism. Int J Obes (Lond). 2014 Sep;38 (9):1251-4
  • Kralisch S, Stepan H, Kratzsch J, Verlohren M, Verlohren HJ, Drynda K, Lossner U, Bluher M, Stumvoll M, Fasshauer M. Serum levels of adipocyte fatty acid binding protein are increased in gestational diabetes mellitus. Eur J Endocrinol. 2009 Jan;160 (1):33-8
  • Lam DC, Xu A, Lam KS, Lam B, Lam JC, Lui MM, Ip MS. Serum adipocyte-fatty acid binding protein level is elevated in severe OSA and correlates with insulin resistance. Eur Respir J. 2009 Feb;33 (2):346-51
  • Lamounier-Zepter V, Look C, Alvarez J, Christ T, Ravens U, Schunck WH, Ehrhart-Bornstein M, Bornstein SR, Morano I. Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ Res. 2009 Aug 14;105 (4):326-34
  • Lazaro I, Diaz M, Cabre A, Masana L, Ibanez L. Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess. Gynecol Endocrinol. 2011 Nov;27 (11):935-9
  • Lazaro I, Ferre R, Plana N, Aragones G, Girona J, Merino J, Heras M, Cabre A, Masana L. Lifestyle changes lower FABP4 plasma concentration in patients with cardiovascular risk. Rev Esp Cardiol. 2012 Feb;65 (2):152-7
  • Lina Y, Lawrence GS, Wijaya A, As'ad S. Angiopoietin like protein 3 (Angptl3), fatty acid binding protein 4 (FABP4) and homeostasis model assessment of insulin resistance (HOMA-IR) among Indonesian obese non diabetic males. Med J Indones. 2010;19 (3):185-190
  • Liu Y, Wang D, Li D, Sun R, Xia M. Associations of retinol-binding protein 4 with oxidative stress, inflammatory markers, and metabolic syndrome in a middle-aged and elderly Chinese population. Diabetol Metab Syndr. 2014;6 (1):25
  • Li B, Yang H, Zhang W, et al. Fatty acid-binding protein 4 predicts gestational hypertension and preeclampsia in women with gestational diabetes mellitus. PLoS One. 2018;13(2):e0192347. Published 2018 Feb 2. doi:10.1371/journal.pone.0192347
  • Lu L, Wang YN, Sun WH, Liu ZH, Zhang Q, Pu LJ, Yang K, Wang LJ, Zhu ZB, Meng H, Yang P, Du R, Chen QJ, Wang LS, Yu H, Shen WF. Two-dimensional fluorescence in-gel electrophoresis of coronary restenosis tissues in minipigs: increased adipocyte fatty acid binding protein induces reactive oxygen species-mediated growth and migration in smooth muscle cells. Arterioscler Thromb Vasc Biol. 2013 Mar;33 (3):572-80
  • Lui MM, Lam JC, Mak HK, Xu A, Ooi C, Lam DC, Mak JC, Khong PL, Ip MS. C-reactive protein is associated with obstructive sleep apnea independent of visceral obesity. Chest. 2009 Apr;135 (4):950-6
  • Messina S, Vargas-Lowy D, Musallam A, Healy B, Healy BC, Gandhi R, Bove R, Gholipour T, Khoury S, Weiner HL, Chitnis T. Increased leptin and A-FABP levels in relapsing and progressive forms of MS. BMC Neurol. 2013 Nov 11;13 (1):172
  • Milner KL, van der Poorten D, Xu A, Bugianesi E, Kench JG, Lam KS, Chisholm DJ, George J. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology. 2009 Jun;49 (6):1926-34
  • Miyoshi T, Doi M, Hirohata S, Kamikawa S, Usui S, Ogawa H, Sakane K, Izumi R, Ninomiya Y, Kusachi S. Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. Heart Vessels. 2010 Nov 10;
  • Miyoshi T, Onoue G, Hirohata A, Hirohata S, Usui S, Hina K, Kawamura H, Doi M, Kusano KF, Kusachi S, Ninomiya Y. Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound. Atherosclerosis. 2010 Jul;211 (1):164-9
  • Mohlig M, Weickert MO, Ghadamgadai E, Machlitt A, Pfuller B, Arafat AM, Pfeiffer AF, Schofl C. Adipocyte fatty acid-binding protein is associated with markers of obesity, but is an unlikely link between obesity, insulin resistance, and hyperandrogenism in polycystic ovary syndrome women. Eur J Endocrinol. 2007 Aug;157 (2):195-200
  • Morieri ML, Guardigni V, Sanz JM, et al. Adipokines levels in HIV infected patients: lipocalin-2 and fatty acid binding protein-4 as possible markers of HIV and antiretroviral therapy-related adipose tissue inflammation. BMC Infect Dis. 2018;18(1):10. Published 2018 Jan 5. doi:10.1186/s12879-017-2925-4
  • Nagaev I, Bokarewa M, Tarkowski A, Smith U. Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes. PLoS One. 2006;1:e31
  • Ni X, Gu Y, Yu H, et al. Serum Adipocyte Fatty Acid-Binding Protein 4 Levels Are Independently Associated with Radioisotope Glomerular Filtration Rate in Type 2 Diabetic Patients with Early Diabetic Nephropathy. Biomed Res Int. 2018;2018:4578140. Published 2018 May 27. doi:10.1155/2018/4578140
  • Novotny D, Vaverkova H, Karasek D, Lukes J, Slavik L, Malina P, Orsag J. Evaluation of total adiponectin, adipocyte fatty acid binding protein and fibroblast growth factor 21 levels in individuals with metabolic syndrome. Physiol Res. 2014;63 (2):219-28
  • Ortega-Senovilla H, Schaefer-Graf U, Meitzner K, Abou-Dakn M, Graf K, Kintscher U, Herrera E. Gestational diabetes mellitus causes changes in the concentrations of adipocyte fatty acid-binding protein and other adipocytokines in cord blood. Diabetes Care. 2011 Sep;34 (9):2061-6
  • Pala L, Monami M, Ciani S, Dicembrini I, Pasqua A, Pezzatini A, Francesconi P, Cresci B, Mannucci E, Rotella CM. Adipokines as possible new predictors of cardiovascular diseases: a case control study. J Nutr Metab. 2012;2012:253428
  • Park SE, Rhee EJ, Lee WY, Kim WJ, Yoo SH, Bae JC, Choi ES, Park CY, Oh KW, Park SW, Kim SW. The role of serum adipocyte fatty acid-binding protein on the development of metabolic syndrome is independent of pro-inflammatory cytokines. Nutr Metab Cardiovasc Dis. 2012 Jun;22 (6):525-32
  • Queipo-Ortuno MI, Escote X, Ceperuelo-Mallafre V, Garrido-Sanchez L, Miranda M, Clemente-Postigo M, Perez-Perez R, Peral B, Cardona F, Fernandez-Real JM, Tinahones FJ, Vendrell J. FABP4 dynamics in obesity: discrepancies in adipose tissue and liver expression regarding circulating plasma levels. PLoS One. 2012;7 (11):e48605
  • Reinehr T, Stoffel-Wagner B, Roth CL. Adipocyte fatty acid-binding protein in obese children before and after weight loss. Metabolism. 2007 Dec;56 (12):1735-41
  • Rhee EJ, Lee WY, Park CY, Oh KW, Kim BJ, Sung KC, Kim BS. The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults. Eur J Endocrinol. 2009 Feb;160 (2):165-72
  • Schmilovitz-Weiss H, Laish I, Levi Z, Monsselise Y, Harif Y, Braun M, Boaz M, Ben-Ari Z. Serum adipocyte fatty acid binding protein in liver transplant recipients and the metabolic syndrome. Ann Hepatol. 2012 May-Jun;11 (3):343-9
  • Scifres CM, Catov JM, Simhan H. Maternal serum fatty acid binding protein 4 (FABP4) and the development of preeclampsia. J Clin Endocrinol Metab. 2012 Mar;97 (3):E349-56
  • Shangguan X, Liu F, Wang H, He J, Dong M. Alterations in serum adipocyte fatty acid binding protein and retinol binding protein-4 in normal pregnancy and preeclampsia. Clin Chim Acta. 2009 Sep;407 (1-2):58-61
  • Shen J, Chan HL, Wong GL, Choi PC, Chan AW, Chan HY, Chim AM, Yeung DK, Chan FK, Woo J, Yu J, Chu WC, Wong VW. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol. 2012 Jun;56 (6):1363-70
  • Siahanidou T, Margeli A, Davradou M, Apostolakou F, Papassotiriou I, Roma E, Mandyla H, Chrousos G. Circulating adipocyte fatty acid binding protein levels in healthy preterm infants: Positive correlation with weight gain and total-cholesterol levels. Early Hum Dev. 2010 Apr;86 (4):197-201
  • Simon I, Escote X, Vilarrasa N, Gomez J, Fernandez-Real JM, Megia A, Gutierrez C, Gallart L, Masdevall C, Vendrell J. Adipocyte fatty acid-binding protein as a determinant of insulin sensitivity in morbid-obese women. Obesity (Silver Spring). 2009 Jun;17 (6):1124-8
  • Sommer G, Ziegelmeier M, Bachmann A, Kralisch S, Lossner U, Kratzsch J, Bluher M, Stumvoll M, Fasshauer M. Serum levels of adipocyte fatty acid-binding protein (AFABP) are increased in chronic haemodialysis (CD). Clin Endocrinol (Oxf). 2008 Dec;69 (6):901-5
  • Sovova E, Hobzova M, Stejskal D, Sova M, Kolek V, Zapletalova J. Treatment of obstructive sleep apnea with continuous positive airway pressure decreases adipocyte fatty acid-binding protein levels. Biomed Pap Med Fac Univ Palack. 2012 Mar;156 (1):58-62
  • Sovova E, Sova M, Zapletalova J, Stejskal D, Sovova M, Kaletova M, Svobodova G, Kuca I, Janak M, Kaminek M. Possitive correlation between adipocyte fatty acid-binding protein and epicardial fat in patients with a family history of cardiovascular disesase. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017 May 16. doi: 10.5507/bp.2017.018. [Epub ahead of print] PubMed PMID: 28539672.
  • Spartano NL, Stevenson MD, Xanthakis V, Larson MG, Andersson C, Murabito JM, Vasan RS. Associations of objective physical activity with insulin sensitivity and circulating adipokine profile: the Framingham Heart Study. Clin Obes. 2017 Apr;7(2):59-69. doi: 10.1111/cob.12177
  • Stefanska A, ORCID: 0000-0002-5295-2236, Ponikowska I, Sypniewska G. A-FABP concentration is more strongly associated with cardiometabolic risk factors and the occurrence of metabolic syndrome in premenopausal than in postmenopausal middle-aged women. Biomed Res Int. 2014;2014:645762
  • Stefanska A, Sypniewska G, Blaszkiewicz B, Ponikowska I, Cwiklinska-Jurkowska M. Comparison between C-reactive protein and adipocyte fatty acid-binding protein as a component of metabolic syndrome in middle-aged women. Clin Biochem. 2011 Mar;44 (4):304-6
  • Stejskal D, Karpisek M. Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome?. Eur J Clin Invest . Sep;36(9):621-5 (2006)
  • Stejskal D, Karpisek M, Bronsky J. Serum adipocyte-fatty acid binding protein discriminates patients with permanent and temporary body weight loss. J Clin Lab Anal. 2008;22 (5):380-2
  • Terra X, Quintero Y, Auguet T, Porras JA, Hernandez M, Sabench F, Aguilar C, Luna AM, Del Castillo D, Richart C. FABP 4 is associated with inflammatory markers and metabolic syndrome in morbidly obese women. Eur J Endocrinol. 2011 Apr;164 (4):539-47
  • Teunissen CE, Elias N, Koel-Simmelink MJ, Durieux-Lu S, Malekzadeh A, Pham TV, Piersma SR, Beccari T, Meeter LH, Dopper EG, van Swieten JC, Jimenez CR, Pijnenburg YA. Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. Alzheimers Dement (Amst). 2016;2:86-94
  • Tonjes A, Kralisch S, Lossner U, Kovacs P, Bluher M, Stumvoll M, Fasshauer M. Metabolic and genetic predictors of circulating adipocyte fatty acid-binding protein. Int J Obes (Lond). 2012 Jun;36 (6):766-73
  • Toruner F, Altinova AE, Akturk M, Kaya M, Arslan E, Bukan N, Kan E, Yetkin I, Arslan M. The relationship between adipocyte fatty acid binding protein-4, retinol binding protein-4 levels and early diabetic nephropathy in patients with type 2 diabetes. Diabetes Res Clin Pract. 2011 Feb;91 (2):203-7
  • Tsai JP, Liou HH, Liu HM, Lee CJ, Lee RP, Hsu BG. Fasting serum fatty acid-binding protein 4 level positively correlates with metabolic syndrome in hemodialysis patients. Arch Med Res. 2010 Oct;41 (7):536-40
  • Tso AW, Xu A, Sham PC, Wat NM, Wang Y, Fong CH, Cheung BM, Janus ED, Lam KS. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes - a 10-year prospective study in Chinese. Diabetes Care . Jul 9 (2007)
  • Tuuri AL, Jauhiainen MS, Tikkanen MJ, Kaaja RJ. Systolic blood pressure and fatty acid-binding protein 4 predict pregnancy-induced hypertension in overweight nulliparous women. Placenta. 2014 Oct;35 (10):797-801
  • Urushima H, Sanada Y, Ogata A, Yoshida M, Lin H, Hagihara K, Narazaki M, Tanaka T, Ito T, Maeda K. Tocilizumab Increases Serum Adiponectin and Reduces Serum Fatty Acid Binding Protein 4 in Patients With Rheumatoid Arthritis. J Endocrinol Metab. 2014;4 ((5-6)):143-7
  • von Eynatten M, Breitling LP, Roos M, Baumann M, Rothenbacher D, Brenner H. Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: a 10-year prospective study. Arterioscler Thromb Vasc Biol. 2012 Sep;32 (9):2327-35
  • von Eynatten M, Luzzi VI, Allolio B, Semenkovich CF, Schneider JG. Circulating Adipocyte-Specific Fatty Acid Binding Protein Levels Are Elevated in Type 2 Diabetes and Coronary Artery Disease.
  • von Eynatten M, Schneider JG, Allolio B. Adipocyte fatty acid binding protein (A-FABP) ist ein neuer Serum-Marker für Adipositas, Insulinresistenz und Metabolisches Syndrom. Diabetologie . 1:S23-S172 (2006)
  • von Jeinsen B, Short MI, Xanthakis V, et al. Association of Circulating Adipokines With Echocardiographic Measures of Cardiac Structure and Function in a Community-Based Cohort. J Am Heart Assoc. 2018;7(13):e008997. Published 2018 Jun 21. doi:10.1161/JAHA
  • Woo YC, Tso AW, Xu A, Law LS, Fong CH, Lam TH, Lo SV, Wat NM, Cheung BM, Lam KS. Combined use of serum adiponectin and tumor necrosis factor-alpha receptor 2 levels was comparable to 2-hour post-load glucose in diabetes prediction. PLoS One. 2012;7 (5):e36868
  • Wu LE, Samocha-Bonet D, Whitworth PT, Fazakerley DJ, Turner N, Biden TJ, James DE, Cantley J. Identification of fatty acid binding protein 4 as an adipokine that regulates insulin secretion during obesity. Molecular Metabolism. 14 March 2014;
  • Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, Yeung DC, Janus ED, Sham PC, Lam KS. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation . Mar 27;115(12):1537-43 (2007)
  • Xu A, Vanhoutte PM. Adiponectin and adipocyte fatty acid binding protein in the pathogenesis of cardiovascular disease. Am J Physiol Heart Circ Physio. 2012 Mar 15;302 (6):H1231-40
  • Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NM, Wong WK, Lam KS. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem . Mar;52(3):405-13 (2006)
  • Yamada M, Mochizuki K, Honma K, Miyauchi R, Kasezawa N, Tohyama K, Goda T. Serum Fatty Acid Binding Protein 4 Concentrations Are Positively and Independently Associated with Blood Pressure and Abdominal Fat among Parameters in Health Check-Ups in Ordinary Middle-Aged Japanese Males. J Nutr Sci Vitaminol (Tokyo). 2015;61 (4):291-8
  • Yeung DC, Lam KS, Wang Y, Tso AW, Xu A. Serum zinc-alpha2-glycoprotein correlates with adiposity, triglycerides, and the key components of the metabolic syndrome in chinese subjects. J Clin Endocrinol Metab. 2009 Jul;94 (7):2531-6
  • Yeung DC, Wang Y, Xu A, Cheung SC, Wat NM, Fong DY, Fong CH, Chau MT, Sham PC, Lam KS. Epidermal fatty-acid-binding protein: a new circulating biomarker associated with cardio-metabolic risk factors and carotid atherosclerosis. Eur Heart J. 2008 Sep;29 (17):2156-63
  • Yeung DC, Xu A, Cheung CW, Wat NM, Yau MH, Fong CH, Chau MT, Lam KS. Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol . Aug;27(8):1796-802 (2007)
  • Yeung DC, Xu A, Tso AW, Chow WS, Wat NM, Fong CH, Tam S, Sham PC, Lam KS. Circulating levels of adipocyte and epidermal fatty acid-binding proteins in relation to nephropathy staging and macrovascular complications in type 2 diabetic patients. Diabetes Care. 2009 Jan;32 (1):132-4
  • Yoo HJ, Kim S, Park MS, Choi HY, Yang SJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Serum adipocyte fatty acid-binding protein is associated independently with vascular inflammation: analysis with (18)F-fluorodeoxyglucose positron emission tomography. J Clin Endocrinol Metab. 2011 Mar;96 (3):E488-92
  • Yun KE, Kim SM, Choi KM, Park HS. Association between adipocyte fatty acid-binding protein levels and childhood obesity in Korean children. Metabolism. 2009 Jun;58 (6):798-802
  • Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RL, Chow WS, Tso AW, Lam KS, Xu A. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008 May;57 (5):1246-53
  • Zhou M, Bao Y, Li H, Pan Y, Shu L, Xia Z, Wu D, Lam KS, Vanhoutte PM, Xu A, Jia W, Hoo RL. Deficiency of adipocyte fatty-acid-binding protein alleviates myocardial ischaemia/reperfusion injury and diabetes-induced cardiac dysfunction. Clin Sci (Lond). 2015 Oct;129 (7):547-59
References to Summary

References to Adipocyte Fatty Acid Binding Protein

  • Makowski L, Brittingham KC, Reynolds JM, Suttles J and Hotamisligil GS: The Fatty Acid-binding Protein, aP2, Coordinates Macrophage Cholesterol Trafficking and Inflammatory Activity. J Biol Chem. 2005 Apr 1.280(13):12888–95.
  • Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, Cao Q, AtsumiG, Malone H, Krishnan B, Minokoshi Y, Kahn BB, Parker RA and Hotamisligil GS: Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metabolism, Volume 1, Issue 2, February 2005, Pages 107–119.
  • Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, Hotamisligil GS: Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation. 2004 Sep 14;110(11):1492–8.
  • Lehmann F, Haile S, Axen E, Medina C, Uppenberg J, Svensson S, Lundback T, Rondahl L, Barf T: Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445–8.
  • Damcott CM, Moffett SP, Feingold E, Barmada MM, Marshall JA, Hamman RF, Ferrell RE: Genetic variation in fatty acid-binding protein-4 and peroxisome proliferatoractivated receptor gamma interactively influence insulin sensitivity and body composition in males. Metabolism. 2004 Mar;53(3):303–9.
  • Jenkins-Kruchten AE, Bennaars-Eiden A, Ross JR, Shen WJ, Kraemer FB, Bernlohr DA: Fatty acid-binding protein-hormone-sensitive lipase interaction. Fatty acid dependence on binding. J Biol Chem. 2003 Nov 28;278(48):47636–43.
  • Hertzel AV, Bennaars-Eiden A, Bernlohr DA: Increased lipolysis in transgenic animals overexpressing the epithelial fatty acid binding protein in adipose cells. J Lipid Res. 2002 Dec;43(12):2105–11.
  • Fu Y, Luo N, Lopes-Virella MF, Garvey WT: The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages. Atherosclerosis. 2002 Dec;165(2):259–69.
  • Storch J, Veerkamp JH, Hsu KT: Similar mechanisms of fatty acid transfer from human anal rodent fatty acid-binding proteins to membranes: liver, intestine, heart muscle, and adipose tissue FABPs. Mol Cell Biochem. 2002 Oct;239(1–2):25–33.
  • Fisher RM, Hoffstedt J, Hotamisligil GS, Thorne A, Ryden M: Effects of obesity and weight loss on the expression of proteins involved in fatty acid metabolism in human adipose tissue. Int J Obes Relat Metab Disord. 2002 Oct;26(10):1379–85.
  • Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, Hotamisligil GS: Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1686–91.
  • Fisher RM, Eriksson P, Hoffstedt J, Hotamisligil GS, Thorne A, Ryden M, Hamsten A, Arner P: Fatty acid binding protein expression in different adipose tissue depots from lean and obese individuals. Diabetologia. 2001 Oct;44(10):1268–73.
  • Scheja L, Makowski L, Uysal KT, Wiesbrock SM, Shimshek DR, Meyers DS, Morgan M, Parker RA, Hotamisligil GS: Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes. 1999 Oct;48(10):1987–94.
  • Coe NR, Simpson MA, Bernlohr DA: Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. J Lipid Res. 1999 May;40(5):967–72.
  • Baxa CA, Sha RS, Buelt MK, Smith AJ, MatareseV, Chinander LL, Boundy KL and Bernlohr DA: Human adipocyte lipid-binding protein: purification of the protein and cloning of its complementary DNA. Biochemistry. 1989; 28 (22), 8683–8690.
Related Products Docs